← Back to headlines
Capricor Therapeutics Receives Review Extension for Deramiocel
Biotech firm Capricor Therapeutics has secured another extension for the regulatory review of its experimental drug Deramiocel, marking continued progress in its development pipeline.
1 Sept, 14:43 — 1 Sept, 14:43
Sources
Showing 1 of 1 sources
